BRCA1 and BRCA2 are tumor suppressor genes. Inherited mutations in these genes dramatically increase lifetime risk of breast, ovarian, pancreatic, and prostate cancer. Genetic testing analyzes your DNA to detect these mutations, helping guide preventive strategies and treatment decisions.

BRCA testing is recommended for individuals with: early-onset breast cancer (under 50), triple-negative breast cancer, ovarian cancer at any age, multiple family members with breast or ovarian cancer, male breast cancer, Ashkenazi Jewish heritage, or a known BRCA mutation in the family.

A positive BRCA result means a pathogenic mutation was found. It doesn't mean you have cancer, but your lifetime risk is significantly higher. Your doctor and genetic counselor will recommend enhanced surveillance, risk-reduction options (chemoprevention or prophylactic surgery), and cascade testing for family members.

A negative result means no BRCA1/BRCA2 mutation was found. If your family has a known mutation and you test negative, that's a true negative — very reassuring. If no family mutation is known, you still carry a general population cancer risk even with a negative result.

Yes. BRCA-mutated cancers are eligible for PARP inhibitor therapies (olaparib, rucaparib, niraparib, talazoparib) approved for breast, ovarian, and prostate cancer. BRCA status also influences platinum chemotherapy sensitivity and immunotherapy decisions.

BRCA1/BRCA2 test results are typically available in 14–21 business days. A certified genetic counselor will help you understand your results and what they mean for you and your family.

Yes. First-degree relatives (parents, siblings, children) have a 50% chance of carrying the same mutation. Cascade testing is strongly recommended so family members can make informed decisions about surveillance and prevention.

A VUS is a gene change detected where clinical significance is not yet established. VUS findings are tracked over time as more data becomes available and may be reclassified to pathogenic or benign. A genetic counselor will explain the implications and monitoring plan.

BRCA1 BRCA2 test cost in India typically ranges from ₹15,000 to ₹45,000 depending on whether you test both genes via full sequencing, a targeted panel, or add reflex hereditary panel testing. BRCA genetic testing cost India and BRCA1 BRCA2 test price India can vary by lab — contact us for current pricing in India.

BRCA2 positive ICD 10 refers to the diagnosis code (Z15.02 for genetic susceptibility to malignant neoplasm, BRCA2) used by your hospital or insurer to document a confirmed BRCA2 gene mutation in your records — it's an administrative/billing code, not a clinical description of severity.

Yes. Upload your existing BRCA1 and BRCA2 test report and our certified genetic counselors will walk you through the BRCA genetic test report interpretation guide — explaining pathogenic, likely pathogenic, VUS, or negative results per NCCN BRCA testing standards — and outline next steps for you and your family.

Being BRCA2 positive means a pathogenic mutation was confirmed in the BRCA2 gene. Next steps typically include enhanced screening (breast MRI, mammogram), discussing risk-reducing surgery or chemoprevention with your oncologist, reviewing PARP inhibitor eligibility if you have an active cancer diagnosis, and arranging cascade testing for first-degree relatives.

Your BRCA1 and BRCA2 test report is reviewed by a certified genetic counselor alongside your oncologist, referencing NCCN BRCA testing and NCBI BRCA1 classification standards — ensuring pathogenic, VUS, or negative findings are explained in clear, actionable terms, not left as a raw lab printout.